Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

You know Hims, right? It's the next-gen telehealth startup famous for taking the eye contact out of erectile dysfunction treatment. Of course, bedroom pills aren't all Hims peddles. The Uberized ...

The stock is up more than 40% since the beginning of the year, peaking in mid-February after Hims & Hers ran a controversial commercial about its weight-loss platform during the Super Bowl and ...

The company’s stock rise reflects investor optimism following the news that Hims & Hers will provide both branded versions of ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Hims & Hers (NYSE: HIMS) has seen incredibly high growth, but the market is skeptical that will continue. In this video, Travis Hoium shows just how cheap the stock is today. *Stock prices used ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operations ...

Apostrophe, a skin care telehealth brand headquartered in the Bay Area, is shutting down after almost four years under the Hims & Hers corporate umbrella. The skin care company, founded in ...

BofA analyst Allen Lutz notes that the Food and Drug Administration yesterday provided updated enforcement timelines for semaglutide and ...